State of New Jersey Common Pension Fund D Trims Stock Holdings in PTC Therapeutics, Inc. $PTCT

State of New Jersey Common Pension Fund D lowered its holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT) by 43.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 24,402 shares of the biopharmaceutical company’s stock after selling 19,078 shares during the period. State of New Jersey Common Pension Fund D’s holdings in PTC Therapeutics were worth $1,854,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Smartleaf Asset Management LLC grew its stake in PTC Therapeutics by 101.3% in the 3rd quarter. Smartleaf Asset Management LLC now owns 469 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 236 shares in the last quarter. Optiver Holding B.V. raised its holdings in PTC Therapeutics by 96.5% during the 3rd quarter. Optiver Holding B.V. now owns 507 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 249 shares during the period. Comerica Bank lifted its position in shares of PTC Therapeutics by 868.5% during the third quarter. Comerica Bank now owns 523 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 469 shares in the last quarter. Salomon & Ludwin LLC bought a new position in shares of PTC Therapeutics in the fourth quarter worth $41,000. Finally, First Horizon Corp bought a new position in shares of PTC Therapeutics in the fourth quarter worth $53,000.

PTC Therapeutics Price Performance

PTC Therapeutics stock opened at $73.69 on Monday. The stock has a market cap of $6.11 billion, a price-to-earnings ratio of -31.63 and a beta of 0.53. The business has a 50-day simple moving average of $67.69 and a 200 day simple moving average of $72.07. PTC Therapeutics, Inc. has a 52 week low of $43.17 and a 52 week high of $87.50.

PTC Therapeutics (NASDAQ:PTCT) last released its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.03) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.42. The firm had revenue of $272.55 million for the quarter, compared to analysts’ expectations of $217.42 million. PTC Therapeutics had a negative return on equity of 362.45% and a negative net margin of 22.58%.The company’s revenue was up 43.5% compared to the same quarter last year. During the same quarter last year, the firm posted $10.04 EPS. On average, research analysts anticipate that PTC Therapeutics, Inc. will post -1.09 earnings per share for the current year.

More PTC Therapeutics News

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: PTC Therapeutics reported Q1 revenue of $273 million and EPS of -$0.03, beating Wall Street estimates on both the top and bottom line. Revenue was up 43.5% year over year, and the company said its updated results support a higher full-year 2026 outlook. PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
• Positive Sentiment: The company raised FY 2026 revenue guidance to $1.1 billion-$1.2 billion, above the market’s prior expectation of about $1.0 billion, signaling stronger commercial momentum. PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
• Positive Sentiment: Wells Fargo lifted its price target on PTCT from $86 to $95 and kept an Overweight rating, suggesting further upside if execution continues. Benzinga report on Wells Fargo price target increase
• Neutral Sentiment: Royal Bank of Canada raised its price target from $81 to $82 while maintaining a Sector Perform rating, indicating a more measured view than Wells Fargo despite still acknowledging some upside. Benzinga report on RBC price target increase
• Neutral Sentiment: Management also highlighted progress in its pipeline and programs, including Sephience launch growth and positive interim data for votoplam, which may support longer-term sentiment but is less immediately impactful than the earnings beat. PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results

Insiders Place Their Bets

In other news, insider Neil Gregory Almstead sold 52,003 shares of the firm’s stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $69.04, for a total transaction of $3,590,287.12. Following the sale, the insider owned 60,137 shares in the company, valued at approximately $4,151,858.48. This trade represents a 46.37% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Lee Scott Golden sold 829 shares of PTC Therapeutics stock in a transaction on Thursday, April 2nd. The stock was sold at an average price of $67.99, for a total transaction of $56,363.71. Following the sale, the executive vice president directly owned 79,115 shares of the company’s stock, valued at $5,379,028.85. This represents a 1.04% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 126,492 shares of company stock valued at $8,634,621 over the last three months. Corporate insiders own 5.50% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on PTCT. Truist Financial upgraded PTC Therapeutics to a “strong-buy” rating in a research note on Wednesday, March 25th. Wall Street Zen downgraded PTC Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, February 21st. Morgan Stanley reaffirmed an “overweight” rating and set a $94.00 target price on shares of PTC Therapeutics in a report on Friday. Jefferies Financial Group downgraded shares of PTC Therapeutics from a “buy” rating to a “hold” rating and lowered their price target for the stock from $91.00 to $76.00 in a report on Monday, March 30th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of PTC Therapeutics in a research report on Friday, February 20th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, PTC Therapeutics has an average rating of “Moderate Buy” and an average price target of $88.36.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.